AR065247A1 - Sal de napadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona,composiciones farmaceuticas que las contienen y usos en el tratamiento del asma y otras enfermedades pulmonares. - Google Patents
Sal de napadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona,composiciones farmaceuticas que las contienen y usos en el tratamiento del asma y otras enfermedades pulmonares.Info
- Publication number
- AR065247A1 AR065247A1 ARP080100526A ARP080100526A AR065247A1 AR 065247 A1 AR065247 A1 AR 065247A1 AR P080100526 A ARP080100526 A AR P080100526A AR P080100526 A ARP080100526 A AR P080100526A AR 065247 A1 AR065247 A1 AR 065247A1
- Authority
- AR
- Argentina
- Prior art keywords
- difluoro
- amino
- phenyletoxi
- hydroxyylate
- hydroxychinolin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 208000019693 Lung disease Diseases 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 108700001623 hexadecaisoleucinomycin Proteins 0.000 title 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 abstract 2
- -1 2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Una sal cristalina de mononapadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolín-2(1H)-ona y sus solvatos farmacéuticamente aceptables. Reivindicacion 2: Una sal, de acuerdo con la reivindicacion 1, que tiene la formula (1) en la que n tiene un valor de 1 o 2 y sus solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200700362A ES2306595B1 (es) | 2007-02-09 | 2007-02-09 | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065247A1 true AR065247A1 (es) | 2009-05-27 |
Family
ID=39365949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100526A AR065247A1 (es) | 2007-02-09 | 2008-02-07 | Sal de napadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona,composiciones farmaceuticas que las contienen y usos en el tratamiento del asma y otras enfermedades pulmonares. |
Country Status (32)
Country | Link |
---|---|
US (1) | US8283342B2 (es) |
EP (1) | EP2121615B1 (es) |
JP (1) | JP5390402B2 (es) |
KR (2) | KR101493538B1 (es) |
CN (1) | CN101679269B (es) |
AR (1) | AR065247A1 (es) |
AT (1) | ATE551323T1 (es) |
AU (1) | AU2008213109B2 (es) |
BR (1) | BRPI0806391A8 (es) |
CA (1) | CA2677610C (es) |
CL (1) | CL2008000404A1 (es) |
CO (1) | CO6231025A2 (es) |
CY (1) | CY1113366T1 (es) |
DK (1) | DK2121615T3 (es) |
EC (1) | ECSP099557A (es) |
ES (2) | ES2306595B1 (es) |
HK (1) | HK1133011A1 (es) |
HR (1) | HRP20120456T1 (es) |
IL (1) | IL199912A (es) |
MX (1) | MX2009008462A (es) |
MY (1) | MY153657A (es) |
NZ (1) | NZ578412A (es) |
PE (2) | PE20081752A1 (es) |
PL (1) | PL2121615T3 (es) |
PT (1) | PT2121615E (es) |
RS (1) | RS52302B (es) |
RU (1) | RU2495029C2 (es) |
SI (1) | SI2121615T1 (es) |
TW (1) | TWI396535B (es) |
UA (1) | UA97829C2 (es) |
WO (1) | WO2008095720A1 (es) |
ZA (1) | ZA200904851B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2296516B1 (es) * | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
UY32297A (es) * | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221055A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2221297A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
CN107722036B (zh) | 2009-05-14 | 2020-09-04 | 天津合美医药科技有限公司 | 噻吩衍生物 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2641900A1 (en) * | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2668941A1 (en) * | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
KR102398639B1 (ko) * | 2017-06-20 | 2022-05-17 | (주) 성운파마코피아 | 아미드 유도체의 염 및 그 제조방법 |
WO2019073052A1 (en) | 2017-10-13 | 2019-04-18 | Treeway Tw001 B.V. | EDARAVONE SALT |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT334335B (de) | 1973-03-01 | 1976-01-10 | Basf Ag | Verfahren zur herstellung von 1-phenyl-2-aminoathanolen-(1) |
US3053865A (en) | 1958-03-19 | 1962-09-11 | Merck & Co Inc | Novel 16-alkyl and 16-alkylene steroids and processes |
GB869511A (en) | 1958-05-26 | 1961-05-31 | Upjohn Co | Improvements in or relating to steroids and the manufacture thereof |
US3007923A (en) | 1959-01-22 | 1961-11-07 | Lab Francais Chimiotherapie | Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids |
US3104246A (en) | 1961-08-18 | 1963-09-17 | Roussel Uclaf | Process of preparation of beta-methasone |
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
GB1247370A (en) | 1968-12-31 | 1971-09-22 | Allen & Hanburys Ltd | Glyoxals and production thereof |
US3678137A (en) | 1970-10-15 | 1972-07-18 | Smith Kline French Lab | Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates |
BE786713A (fr) | 1971-07-27 | 1973-01-25 | Sandoz Sa | Nouveaux amino-alcools, leur preparation et leur application comme medicaments |
SE378109B (es) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US3975391A (en) | 1973-12-26 | 1976-08-17 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
US4068076A (en) | 1972-12-29 | 1978-01-10 | Otsuka Pharmaceutical Co., Ltd. | 5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
DE2310140A1 (de) | 1973-03-01 | 1974-09-12 | Basf Ag | Neue 1-phenyl-2-amino-aethanolderivate und ein verfahren zu ihrer herstellung |
GB1468156A (en) | 1973-07-19 | 1977-03-23 | Ici Ltd | Phenylethylamine derivatives |
US4026897A (en) | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
US4022784A (en) | 1974-01-31 | 1977-05-10 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives |
JPS5649907B2 (es) | 1974-02-01 | 1981-11-25 | ||
US4145542A (en) | 1974-06-13 | 1979-03-20 | Otsuka Pharmaceutical Co., Ltd. | 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
US3994901A (en) | 1974-06-13 | 1976-11-30 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
JPS597706B2 (ja) | 1975-06-13 | 1984-02-20 | オオツカセイヤク カブシキガイシヤ | カルボスチリルユウドウタイノセイゾウホウ |
DE2965655D1 (en) | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
JPS6010032B2 (ja) | 1983-10-31 | 1985-03-14 | 大塚製薬株式会社 | カルボスチリル誘導体 |
GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
PH24383A (en) | 1984-06-11 | 1990-06-13 | Glaxo Group Ltd | Ethanolamine |
FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
EP0286242A3 (en) | 1987-03-12 | 1989-08-09 | Glaxo Group Limited | Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them |
DK633588A (da) | 1987-11-13 | 1989-05-14 | Glaxo Group Ltd | Aminderivater |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
JPH03178929A (ja) | 1989-09-07 | 1991-08-02 | Glaxo Group Ltd | 炎症及びアレルギー治療用化合物 |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
US5507281A (en) | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
EP0503031B1 (en) | 1990-09-26 | 1998-04-01 | Pharmachemie B.V. | Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber |
GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
AU683036B2 (en) | 1992-12-18 | 1997-10-30 | Merck Sharp & Dohme Corp. | Inhaler for powdered medications |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
SK284303B6 (sk) | 1995-06-21 | 2005-01-03 | Sofotec Gmbh & Co. Kg | Puzdro na farmaceutický prášok pre inhalátory na práškové liečivá a inhalátor na práškové liečivá |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
CA2252531A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
DE69711519T2 (de) | 1996-09-05 | 2002-10-31 | Eli Lilly And Co., Indianapolis | Carbazolanaloge als selektive beta3-adrenergische Agonisten |
AU4248597A (en) | 1996-09-06 | 1998-03-26 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
AUPQ407699A0 (en) | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
ES2292604T5 (es) | 2000-08-05 | 2015-06-01 | Glaxo Group Limited | Éster S-fluorometílico del ácido 6 ,9 -difluoro-17 -[(2-furanilcarbonil)oxi]-11 -hidroxi-16 -metil-3-oxo-androsta-1,4-dien-17 -carbotioico como agente antiinflamatorio |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
PE20050973A1 (es) * | 2003-10-29 | 2005-11-19 | Theravance Inc | Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
EP1574501A1 (en) * | 2004-03-11 | 2005-09-14 | Pfizer Limited | Quinolinone derivatives, pharmaceutical compositions containing them and their use |
EP1577291A1 (en) | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylethanolamine derivatives as beta-2 agonists |
AP2315A (en) | 2004-03-23 | 2011-11-04 | Pfizer | Formamide derivatives useful as adrenoceptor. |
CA2562532C (en) * | 2004-04-09 | 2010-02-16 | Hanmi Pharm. Co., Ltd. | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same |
RU2006146042A (ru) | 2004-06-03 | 2008-07-20 | Тереванс | Диаминные агонисты 2-адренергических рецепторов |
JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
TW200613275A (en) * | 2004-08-24 | 2006-05-01 | Recordati Ireland Ltd | Lercanidipine salts |
WO2006099166A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Crystalline forms of a biphenyl compound |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2296516B1 (es) | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2302447B1 (es) | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2320961B1 (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
EP2096105A1 (en) | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
-
2007
- 2007-02-09 ES ES200700362A patent/ES2306595B1/es active Active
-
2008
- 2008-02-07 PE PE2008000273A patent/PE20081752A1/es not_active Application Discontinuation
- 2008-02-07 PE PE2012001001A patent/PE20121521A1/es not_active Application Discontinuation
- 2008-02-07 AR ARP080100526A patent/AR065247A1/es not_active Application Discontinuation
- 2008-02-07 CL CL200800404A patent/CL2008000404A1/es unknown
- 2008-02-08 UA UAA200909064A patent/UA97829C2/uk unknown
- 2008-02-08 PT PT08707620T patent/PT2121615E/pt unknown
- 2008-02-08 AT AT08707620T patent/ATE551323T1/de active
- 2008-02-08 EP EP08707620A patent/EP2121615B1/en active Active
- 2008-02-08 KR KR1020097016590A patent/KR101493538B1/ko active IP Right Grant
- 2008-02-08 WO PCT/EP2008/000975 patent/WO2008095720A1/en active Application Filing
- 2008-02-08 MY MYPI20093274A patent/MY153657A/en unknown
- 2008-02-08 SI SI200830677T patent/SI2121615T1/sl unknown
- 2008-02-08 US US12/526,090 patent/US8283342B2/en not_active Expired - Fee Related
- 2008-02-08 BR BRPI0806391A patent/BRPI0806391A8/pt not_active IP Right Cessation
- 2008-02-08 RU RU2009133442/04A patent/RU2495029C2/ru active
- 2008-02-08 JP JP2009548626A patent/JP5390402B2/ja not_active Expired - Fee Related
- 2008-02-08 NZ NZ578412A patent/NZ578412A/en not_active IP Right Cessation
- 2008-02-08 AU AU2008213109A patent/AU2008213109B2/en not_active Ceased
- 2008-02-08 CA CA2677610A patent/CA2677610C/en active Active
- 2008-02-08 MX MX2009008462A patent/MX2009008462A/es active IP Right Grant
- 2008-02-08 KR KR1020147032769A patent/KR20140140651A/ko not_active Application Discontinuation
- 2008-02-08 RS RS20120226A patent/RS52302B/en unknown
- 2008-02-08 CN CN2008800043230A patent/CN101679269B/zh not_active Expired - Fee Related
- 2008-02-08 DK DK08707620.4T patent/DK2121615T3/da active
- 2008-02-08 PL PL08707620T patent/PL2121615T3/pl unknown
- 2008-02-08 ES ES08707620T patent/ES2384905T3/es active Active
- 2008-02-12 TW TW097104853A patent/TWI396535B/zh not_active IP Right Cessation
-
2009
- 2009-07-10 ZA ZA200904851A patent/ZA200904851B/xx unknown
- 2009-07-16 IL IL199912A patent/IL199912A/en active IP Right Grant
- 2009-08-04 EC EC2009009557A patent/ECSP099557A/es unknown
- 2009-08-06 CO CO09082396A patent/CO6231025A2/es not_active Application Discontinuation
- 2009-12-21 HK HK09112013.9A patent/HK1133011A1/xx not_active IP Right Cessation
-
2012
- 2012-05-28 HR HRP20120456AT patent/HRP20120456T1/hr unknown
- 2012-06-13 CY CY20121100543T patent/CY1113366T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065247A1 (es) | Sal de napadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona,composiciones farmaceuticas que las contienen y usos en el tratamiento del asma y otras enfermedades pulmonares. | |
CL2011001544A1 (es) | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-(r)-hidroxietil}-8-hidroxiquinolin-2(1h)-ona; agonista de los receptores beta 2 adrenergico; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma o enfermedad pulmonar obstructiva cronica. | |
MX2010004576A (es) | Derivados de pirimidina novedosos. | |
CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
MX2014000354A (es) | Quinazolinas sustituidas, su preparacion y su uso en composiciones farmaceuticas. | |
SG10201803862UA (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
EP3828186A3 (en) | Pyrimidinones as factor xia inhibitors | |
TNSN08326A1 (en) | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
MX2014002113A (es) | Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso. | |
PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
CL2007002274A1 (es) | Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras. | |
MY146623A (en) | Substituted prolinamides, manufacturing, and the use thereof as medicaments | |
GEP20186938B (en) | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | |
WO2014152965A3 (en) | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets | |
CL2015002606A1 (es) | Compuesto. | |
CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
GT201100336A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
TW200801022A (en) | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | |
MY149854A (en) | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
WO2011160024A3 (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
MY173573A (en) | Pyridin-4-yl derivatives | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |